|
US7646707B2
(en)
*
|
2003-12-23 |
2010-01-12 |
At&T Intellectual Property I, L.P. |
Method and system for automatically renaming logical circuit identifiers for rerouted logical circuits in a data network
|
|
EP1715882A4
(en)
*
|
2004-01-16 |
2009-04-08 |
Univ Michigan |
SMAC-PEPTIDOMIMETIKA AND ITS USES
|
|
BRPI0506883A
(pt)
*
|
2004-01-16 |
2007-05-29 |
Univ Michigan |
miméticos de smac conformacionalmente comprimidos e seus usos
|
|
EP1735307B1
(en)
|
2004-04-07 |
2012-08-29 |
Novartis AG |
Inhibitors of iap
|
|
RS53734B1
(en)
*
|
2004-07-02 |
2015-06-30 |
Genentech Inc. |
IAP INHIBITORS
|
|
WO2006010118A2
(en)
*
|
2004-07-09 |
2006-01-26 |
The Regents Of The University Of Michigan |
Conformationally constrained smac mimetics and the uses thereof
|
|
EP1773348A4
(en)
*
|
2004-07-12 |
2009-05-20 |
Idun Pharmaceuticals Inc |
TETRA PEPTIDE ANALOGS
|
|
US7456209B2
(en)
|
2004-07-15 |
2008-11-25 |
Tetralogic Pharmaceuticals Corporation |
IAP binding compounds
|
|
KR20120127754A
(ko)
|
2004-12-20 |
2012-11-23 |
제넨테크, 인크. |
Ｉａｐ의 피롤리딘 억제제
|
|
EP1851200B1
(en)
|
2005-02-25 |
2014-01-15 |
Tetralogic Pharmaceuticals Corporation |
Dimeric iap inhibitors
|
|
EP1883627B1
(en)
|
2005-05-18 |
2018-04-18 |
Pharmascience Inc. |
Bir domain binding compounds
|
|
US20100256046A1
(en)
*
|
2009-04-03 |
2010-10-07 |
Tetralogic Pharmaceuticals Corporation |
Treatment of proliferative disorders
|
|
US20070042428A1
(en)
*
|
2005-08-09 |
2007-02-22 |
Stacy Springs |
Treatment of proliferative disorders
|
|
EP1951698A4
(en)
|
2005-10-25 |
2010-04-28 |
Aegera Therapeutics Inc |
BINDING COMPOUNDS TO THE IAP BIR DOMAIN
|
|
CN101374829A
(zh)
*
|
2005-12-19 |
2009-02-25 |
健泰科生物技术公司 |
Iap的抑制剂
|
|
TWI543988B
(zh)
|
2006-03-16 |
2016-08-01 |
科學製藥股份有限公司 |
結合於細胞凋亡抑制蛋白（ｉａｐ）之桿狀病毒ｉａｐ重複序列（ｂｉｒ）區域之化合物
|
|
SG10201407457UA
(en)
|
2006-05-16 |
2014-12-30 |
Pharmascience Inc |
Iap bir domain binding compounds
|
|
US20100143499A1
(en)
*
|
2006-07-24 |
2010-06-10 |
Tetralogic Pharmaceuticals Corporation |
Dimeric iap inhibitors
|
|
WO2008014240A2
(en)
*
|
2006-07-24 |
2008-01-31 |
Tetralogic Pharmaceuticals Corporation |
Dimeric iap inhibitors
|
|
WO2008014229A2
(en)
*
|
2006-07-24 |
2008-01-31 |
Tetralogic Pharmaceuticals Corporation |
Dimeric iap inhibitors
|
|
WO2008014252A2
(en)
|
2006-07-24 |
2008-01-31 |
Tetralogic Pharmaceuticals Corporation |
Iap inhibitors
|
|
AR063943A1
(es)
|
2006-07-24 |
2009-03-04 |
Tetralogic Pharmaceuticals Cor |
Dipeptidos antagonistas de iap, una composicion farmaceutica que los comprende y el uso de los mismos para el tratamiento del cancer.
|
|
WO2008014236A1
(en)
*
|
2006-07-24 |
2008-01-31 |
Tetralogic Pharmaceuticals Corporation |
Dimeric iap inhibitors
|
|
PE20110217A1
(es)
|
2006-08-02 |
2011-04-01 |
Novartis Ag |
DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS
|
|
RU2009110254A
(ru)
*
|
2006-08-24 |
2010-09-27 |
Новартис АГ (CH) |
Производные 2-(пиразин-2-ил)тиазола и 2-(1н-пиразол-3-ил)тиразола и связанные с ним соединения в качестве ингибиторов стеароил-соа десатуразы для лечения метаболических, сердечно-сосудистых и других нарушений
|
|
RU2009114857A
(ru)
*
|
2006-09-22 |
2010-10-27 |
Новартис АГ (CH) |
Гетероциклические органические соединения
|
|
US8044209B2
(en)
|
2006-10-12 |
2011-10-25 |
Novartis Ag |
Pyrrolydine derivatives as IAP inhibitors
|
|
CN101605786A
(zh)
*
|
2006-12-19 |
2009-12-16 |
健泰科生物技术公司 |
细胞凋亡抑制剂的咪唑并吡啶抑制剂
|
|
KR20090091337A
(ko)
*
|
2006-12-20 |
2009-08-27 |
노파르티스 아게 |
Ｓｃｄ 억제제로서의 ２-치환 ５-원 헤테로사이클
|
|
BRPI0810178A2
(pt)
*
|
2007-04-12 |
2014-09-23 |
Joyant Pharmaceuticals Inc |
Dímeros e trímeros miméticos de smac úteis como agentes anticâncer
|
|
CL2008001234A1
(es)
|
2007-04-30 |
2008-09-22 |
Genentech Inc |
Compuestos derivados de heterociclos nitrogenados, inhibidores de las proteinas de apoptosis; y uso en el tratamiento del cancer.
|
|
US20110008802A1
(en)
*
|
2007-05-07 |
2011-01-13 |
Tetralogic Pharmaceuticals Corp. |
TNFalpha GENE EXPRESSION AS A BIOMARKER OF SENSITIVITY TO ANTAGONISTS OF INHIBITOR OF APOPTOSIS PROTEINS
|
|
WO2008144925A1
(en)
*
|
2007-05-30 |
2008-12-04 |
Aegera Therapeutics Inc. |
Iap bir domain binding compounds
|
|
DK2240506T3
(da)
*
|
2008-01-11 |
2013-04-08 |
Genentech Inc |
IAP inhibitorer
|
|
WO2009136290A1
(en)
*
|
2008-05-05 |
2009-11-12 |
Aegera Therapeutics, Inc. |
Functionalized pyrrolidines and use thereof as iap inhibitors
|
|
WO2009155709A1
(en)
*
|
2008-06-27 |
2009-12-30 |
Aegera Therapeutics Inc. |
Bridged secondary amines and use thereof as iap bir domain binding compounds
|
|
NZ590550A
(en)
|
2008-08-02 |
2013-05-31 |
Genentech Inc |
Inhibitors of Apoptosis (IAP) for treating cancer
|
|
CA2730357A1
(en)
*
|
2008-08-16 |
2010-02-25 |
Genetech, Inc. |
Azaindole inhibitors of iap
|
|
EP2328412A4
(en)
|
2008-09-17 |
2012-03-14 |
Tetralogic Pharm Corp |
IPA INHIBITORS
|
|
FR2939073B1
(fr)
|
2008-12-03 |
2010-12-31 |
Sidel Participations |
Formage des recipients avec contre-pression localisee
|
|
US20100317593A1
(en)
*
|
2009-06-12 |
2010-12-16 |
Astrazeneca Ab |
2,3-dihydro-1h-indene compounds
|
|
US8283372B2
(en)
|
2009-07-02 |
2012-10-09 |
Tetralogic Pharmaceuticals Corp. |
2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic
|
|
JP2013505446A
(ja)
|
2009-09-18 |
2013-02-14 |
ノバルティス アーゲー |
Ｉａｐ阻害剤化合物のためのバイオマーカー
|
|
JP5529282B2
(ja)
|
2009-10-28 |
2014-06-25 |
ジョイアント ファーマスーティカルズ、インク． |
二量体Ｓｍａｃ模倣薬
|
|
CN102050867A
(zh)
*
|
2009-11-10 |
2011-05-11 |
上海艾力斯医药科技有限公司 |
四肽类似物、制备方法及其应用
|
|
RU2567544C2
(ru)
|
2010-02-12 |
2015-11-10 |
Фармасайенс Инк. |
Bir домен iap связывающие соединения
|
|
AU2011240070A1
(en)
|
2010-04-16 |
2012-11-08 |
Bayer Intellectual Property Gmbh |
Heterocyclic compounds as pest control agents
|
|
GB201106817D0
(en)
|
2011-04-21 |
2011-06-01 |
Astex Therapeutics Ltd |
New compound
|
|
WO2013043591A1
(en)
*
|
2011-09-21 |
2013-03-28 |
Albert Einstein College Of Medicine Of Yeshiva University |
Combination therapy for cancer
|
|
WO2013049350A1
(en)
|
2011-09-30 |
2013-04-04 |
Tetralogic Pharmaceuticals Corporation |
Smac mimetic (birinapant) for use in the treatment of proliferative diseases (cancer)
|
|
NO2755614T3
(enrdf_load_html_response)
|
2012-01-03 |
2018-03-31 |
|
|
|
TW201347760A
(zh)
|
2012-05-04 |
2013-12-01 |
Novartis Ag |
用於ｉａｐ抑制劑治療之生物標記
|
|
CA2896577C
(en)
|
2012-11-30 |
2024-01-23 |
Sanford-Burnham Medical Research Institute |
Inhibitor of apoptosis protein (iap) antagonists
|
|
US9498532B2
(en)
|
2013-03-13 |
2016-11-22 |
Novartis Ag |
Antibody drug conjugates
|
|
CN105007950B
(zh)
|
2013-03-15 |
2019-01-15 |
诺华股份有限公司 |
抗体药物缀合物
|
|
EA036275B1
(ru)
|
2013-06-25 |
2020-10-21 |
Дзе Уолтер Энд Элиза Хол Инститьют Оф Медикал Рисерч |
Способ лечения внутриклеточной инфекции
|
|
GB201311891D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compound
|
|
GB201311888D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
|
EP3686200A3
(en)
|
2013-12-20 |
2020-09-09 |
Astex Therapeutics Ltd |
Bicyclic heterocycle compounds and their uses in therapy
|
|
WO2015109391A1
(en)
|
2014-01-24 |
2015-07-30 |
Children's Hospital Of Eastern Ontario Research Institute Inc. |
Smc combination therapy for the treatment of cancer
|
|
US20180228907A1
(en)
|
2014-04-14 |
2018-08-16 |
Arvinas, Inc. |
Cereblon ligands and bifunctional compounds comprising the same
|
|
WO2015168835A1
(en)
*
|
2014-05-05 |
2015-11-12 |
Empire Technology Development Llc |
Composite task processor
|
|
US10300074B2
(en)
|
2014-06-04 |
2019-05-28 |
Sanford Burnham Prebys Medical Discovery Institute |
Use of inhibitor of apoptosis protein (IAP) antagonists in HIV therapy
|
|
WO2016020791A1
(en)
|
2014-08-05 |
2016-02-11 |
Novartis Ag |
Ckit antibody drug conjugates
|
|
CA2954599A1
(en)
|
2014-08-12 |
2016-02-18 |
Novartis Ag |
Anti-cdh6 antibody drug conjugates
|
|
GB201414730D0
(en)
*
|
2014-08-19 |
2014-10-01 |
Tpp Global Dev Ltd |
Pharmaceutical compound
|
|
WO2016079527A1
(en)
|
2014-11-19 |
2016-05-26 |
Tetralogic Birinapant Uk Ltd |
Combination therapy
|
|
WO2016097773A1
(en)
|
2014-12-19 |
2016-06-23 |
Children's Cancer Institute |
Therapeutic iap antagonists for treating proliferative disorders
|
|
US12312316B2
(en)
|
2015-01-20 |
2025-05-27 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of androgen receptor
|
|
AU2016209349B2
(en)
|
2015-01-20 |
2020-05-07 |
Arvinas, Inc. |
Compounds and methods for the targeted degradation of the Androgen Receptor
|
|
EP3302482A4
(en)
|
2015-06-05 |
2018-12-19 |
Arvinas, Inc. |
Tank-binding kinase-1 protacs and associated methods of use
|
|
WO2016203432A1
(en)
|
2015-06-17 |
2016-12-22 |
Novartis Ag |
Antibody drug conjugates
|
|
US10772962B2
(en)
|
2015-08-19 |
2020-09-15 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of bromodomain-containing proteins
|
|
MA44334A
(fr)
|
2015-10-29 |
2018-09-05 |
Novartis Ag |
Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
|
|
DK3472149T3
(da)
|
2016-06-21 |
2023-11-27 |
Orion Ophthalmology LLC |
Heterocykliske prolinamidderivater
|
|
US10526315B2
(en)
|
2016-06-21 |
2020-01-07 |
Orion Ophthalmology LLC |
Carbocyclic prolinamide derivatives
|
|
KR102570992B1
(ko)
|
2016-11-01 |
2023-08-28 |
아비나스 오퍼레이션스, 인코포레이티드 |
타우(Tau)-단백질 표적화 프로탁(PROTAC) 및 관련 사용 방법
|
|
HUE064609T2
(hu)
|
2016-12-01 |
2024-04-28 |
Arvinas Operations Inc |
Tetrahidronaftalin és tetrahidroizokinolin származékok mint ösztrogénreceptor-lebontó anyagok
|
|
US10806737B2
(en)
|
2016-12-23 |
2020-10-20 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of fetal liver kinase polypeptides
|
|
EP3558994A4
(en)
|
2016-12-23 |
2021-05-12 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides
|
|
US11173211B2
(en)
|
2016-12-23 |
2021-11-16 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides
|
|
US10994015B2
(en)
|
2016-12-23 |
2021-05-04 |
Arvinas Operations, Inc. |
EGFR proteolysis targeting chimeric molecules and associated methods of use
|
|
US11191741B2
(en)
|
2016-12-24 |
2021-12-07 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
|
|
MX2019008934A
(es)
|
2017-01-26 |
2019-11-05 |
Arvinas Operations Inc |
Moduladores de la proteolisis del receptor de estrogeno y métodos asociados de uso,.
|
|
JOP20190187A1
(ar)
|
2017-02-03 |
2019-08-01 |
Novartis Ag |
مترافقات عقار جسم مضاد لـ ccr7
|
|
US11179413B2
(en)
|
2017-03-06 |
2021-11-23 |
Novartis Ag |
Methods of treatment of cancer with reduced UBB expression
|
|
WO2018185618A1
(en)
|
2017-04-03 |
2018-10-11 |
Novartis Ag |
Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment
|
|
AR111651A1
(es)
|
2017-04-28 |
2019-08-07 |
Novartis Ag |
Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
|
|
MY206158A
(en)
|
2017-05-24 |
2024-12-02 |
Novartis Ag |
Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer
|
|
US20200362058A1
(en)
|
2017-05-24 |
2020-11-19 |
Novartis Ag |
Antibody-cytokine engrafted proteins and methods of use
|
|
WO2018215937A1
(en)
|
2017-05-24 |
2018-11-29 |
Novartis Ag |
Interleukin-7 antibody cytokine engrafted proteins and methods of use in the treatment of cancer
|
|
SG11202004377XA
(en)
*
|
2017-11-13 |
2020-06-29 |
Chia Tai Tianqing Pharmaceutical Group Co Ltd |
Smac mimetics used as iap inhibitors and use thereof
|
|
EP3710443A1
(en)
|
2017-11-17 |
2020-09-23 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides
|
|
JP7161849B2
(ja)
*
|
2018-01-24 |
2022-10-27 |
株式会社クラレ |
第一級アミンの製造方法
|
|
WO2019154053A1
(zh)
*
|
2018-02-09 |
2019-08-15 |
广东东阳光药业有限公司 |
Iap抑制剂及其在药物中的应用
|
|
CN112218859B
(zh)
|
2018-04-04 |
2024-10-29 |
阿尔维纳斯运营股份有限公司 |
蛋白水解调节剂及相关使用方法
|
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
|
HRP20231295T1
(hr)
|
2018-07-10 |
2024-02-02 |
Novartis Ag |
Derivati 3-(5-hidroksi-1-oksoizoindolin-2-il)piperidin-2,6-diona i njihova upotreba u liječenju bolesti ovisnih o cinkovom prstu 2 (ikzf2) obitelji ikaros
|
|
US20200038513A1
(en)
|
2018-07-26 |
2020-02-06 |
Arvinas Operations, Inc. |
Modulators of fak proteolysis and associated methods of use
|
|
CN112912376A
(zh)
|
2018-08-20 |
2021-06-04 |
阿尔维纳斯运营股份有限公司 |
用于治疗神经变性疾病的具有E3泛素连接酶结合活性并靶向α-突触核蛋白的蛋白水解靶向嵌合(PROTAC)化合物
|
|
KR20240028539A
(ko)
|
2018-09-07 |
2024-03-05 |
아비나스 오퍼레이션스, 인코포레이티드 |
급속 진행형 섬유육종 폴리펩티드의 표적화 분해를 위한 다중 고리 화합물 및 방법
|
|
US20230053449A1
(en)
|
2018-10-31 |
2023-02-23 |
Novartis Ag |
Dc-sign antibody drug conjugates
|
|
AU2019402189B2
(en)
|
2018-12-20 |
2023-04-13 |
Novartis Ag |
Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
|
|
EP4406555A3
(en)
|
2018-12-21 |
2024-11-06 |
Novartis AG |
Antibodies to pmel17 and conjugates thereof
|
|
JP7483732B2
(ja)
|
2019-02-15 |
2024-05-15 |
ノバルティス アーゲー |
３－（１－オキソ－５－（ピペリジン－４－イル）イソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用
|
|
CA3123519A1
(en)
|
2019-02-15 |
2020-08-20 |
Novartis Ag |
Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
AU2020233068B2
(en)
*
|
2019-03-07 |
2025-04-24 |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Combination of IAP inhibitor and immune checkpoint inhibitor
|
|
US20220177453A1
(en)
*
|
2019-05-10 |
2022-06-09 |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Crystallization of smac mimic used as iap inhibitor and preparation method thereof
|
|
CN119954801A
(zh)
|
2019-07-17 |
2025-05-09 |
阿尔维纳斯运营股份有限公司 |
Tau蛋白靶向化合物及相关使用方法
|
|
JP2022542437A
(ja)
|
2019-08-02 |
2022-10-03 |
ランティオペプ ベスローテン ヴェンノーツハップ |
癌の処置に用いるアンジオテンシン２型（ａｔ２）受容体アゴニスト
|
|
US12208095B2
(en)
|
2019-08-26 |
2025-01-28 |
Arvinas Operations, Inc. |
Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders
|
|
US20230056470A1
(en)
|
2019-12-20 |
2023-02-23 |
Novartis Ag |
Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases
|
|
CN114980883A
(zh)
|
2020-01-20 |
2022-08-30 |
阿斯利康(瑞典)有限公司 |
用于治疗癌症的表皮生长因子受体酪氨酸激酶抑制剂
|
|
CN111205232B
(zh)
*
|
2020-02-26 |
2022-07-01 |
浙江天宇药业股份有限公司 |
一种替格瑞洛中间体的合成方法
|
|
US20230181756A1
(en)
|
2020-04-30 |
2023-06-15 |
Novartis Ag |
Ccr7 antibody drug conjugates for treating cancer
|
|
CA3185455A1
(en)
|
2020-06-11 |
2021-12-16 |
Novartis Ag |
Zbtb32 inhibitors and uses thereof
|
|
BR112022026202A2
(pt)
|
2020-06-23 |
2023-01-17 |
Novartis Ag |
Regime de dosagem compreendendo derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona
|
|
CN116134027B
(zh)
|
2020-08-03 |
2025-01-24 |
诺华股份有限公司 |
杂芳基取代的3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途
|
|
US12180193B2
(en)
|
2020-08-28 |
2024-12-31 |
Arvinas Operations, Inc. |
Accelerating fibrosarcoma protein degrading compounds and associated methods of use
|
|
EP4211128A1
(en)
|
2020-09-14 |
2023-07-19 |
Arvinas Operations, Inc. |
Crystalline forms of a compound for the targeted degradation of estrogen receptor
|
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
|
|
WO2022221720A1
(en)
|
2021-04-16 |
2022-10-20 |
Novartis Ag |
Antibody drug conjugates and methods for making thereof
|
|
AR125874A1
(es)
|
2021-05-18 |
2023-08-23 |
Novartis Ag |
Terapias de combinación
|
|
WO2023214325A1
(en)
|
2022-05-05 |
2023-11-09 |
Novartis Ag |
Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
|
|
WO2024023666A1
(en)
|
2022-07-26 |
2024-02-01 |
Novartis Ag |
Crystalline forms of an akr1c3 dependent kars inhibitor
|
|
TW202432544A
(zh)
|
2022-09-07 |
2024-08-16 |
美商亞文納營運公司 |
快速加速纖維肉瘤降解化合物及相關使用方法
|